PART I . Overview We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimers disease, or AD. Alzheimers disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. Alzheimers disease is currently estimated to affect approximately seven million people in the United States and approximately 55 million peo...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001628280-26-021413 | EDGAR | 84K words |
| 2025-03-27 | 2024-12-31 | 0001576885-25-000049 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001576885-24-000047 | EDGAR | — |
| 2023-03-27 | 2022-12-31 | 0001576885-23-000017 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001193125-22-086775 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001576885-25-000104 | EDGAR | 19K words |
| 2025-08-12 | 2025-06-30 | 0001576885-25-000093 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001576885-25-000065 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001576885-24-000098 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001576885-24-000092 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001576885-24-000064 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001576885-23-000062 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001576885-23-000050 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001576885-23-000025 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001193125-22-284583 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001193125-22-221297 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001193125-22-151851 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001628280-26-021189 | EDGAR | 3K words |
| 2026-03-16 | 0001628280-26-017885 | EDGAR | — |
| 2026-01-12 | 0001628280-26-001774 | EDGAR | — |
| 2025-11-12 | 0001576885-25-000102 | EDGAR | — |
| 2025-11-10 | 0001628280-25-050800 | EDGAR | — |
| 2025-08-12 | 0001576885-25-000091 | EDGAR | — |
| 2025-07-15 | 0001576885-25-000087 | EDGAR | — |
| 2025-06-05 | 0001576885-25-000072 | EDGAR | — |
| 2025-05-13 | 0001576885-25-000062 | EDGAR | — |
| 2025-03-27 | 0001576885-25-000044 | EDGAR | — |
81 total filings indexed. 54 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001576885 |
| Ticker | ABOS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.acumenpharm.com |
| Listed | 2021-07-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ABOS (~200 tokens, structured JSON with cryptographic provenance)